GGrantIndex
← Leaderboards

Matthew R Allen

Rlr Va Medical Center

$4,949,850
Attributed
$8,425,874
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,425,874 · 7
VA$0 · 2

By mechanism

R01$7,499,429 · 4
R21$422,345 · 1
P30$270,100 · 1
R25$234,000 · 1
I01$0 · 1
IK6$0 · 1

Top collaborators

Most similar at Rlr Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Bone

Research focus

BoneMechanicsFractureTissuesSkeletalAffectPropertyChronic Kidney FailureAnimalsOsteoporosisBone QualityRattusClinicAnimal ModelMineralsDoseBisphosphonateIn VivoKidney DiseasesFda ApprovedExperimental StudyCollagenFracture RiskBone Mass

Grant awards (35)

Uremic toxins and osteocyte dysfunction in CKD$550,066
R01 · FY2025 · DK
Precision medicine approaches to renal osteodystrophy$500,152
R01 · FY2025 · DK
Histology and Histomorphometry Core (HHC)$127,943
P30 · FY2025 · AR · contact PI
Clinical and Translational Science Workforce Development through a Statewide Community College Partnership$108,000
R25 · FY2025 · TR · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Uremic toxins and osteocyte dysfunction in CKD$598,846
R01 · FY2024 · DK
Precision medicine approaches to renal osteodystrophy$517,994
R01 · FY2024 · DK
Histology and Histomorphometry Core (HHC)$142,157
P30 · FY2024 · AR · contact PI
Clinical and Translational Science Workforce Development through a Statewide Community College Partnership$18,000
R25 · FY2024 · TR · contact PI
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2024 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Precision medicine approaches to renal osteodystrophy$550,039
R01 · FY2023 · DK
Clinical and Translational Science Workforce Development through a Statewide Community College Partnership$108,000
R25 · FY2023 · TR · contact PI
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2023 · VA · contact PI
Precision medicine approaches to renal osteodystrophy$581,086
R01 · FY2022 · DK
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2022 · VA · contact PI
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2021 · VA · contact PI
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.$431,326
R01 · FY2019 · DK
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2019 · VA · contact PI
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.$461,139
R01 · FY2018 · DK
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2018 · VA · contact PI
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.$470,578
R01 · FY2017 · DK
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2017 · VA · contact PI
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.$471,810
R01 · FY2016 · DK
Enhancing bone strength using combination drug therapy$322,702
R01 · FY2016 · AR · contact PI
Treating bone deterioration associated with chronic kidney disease$0
I01 · FY2016 · VA · contact PI
Enhancing bone strength using combination drug therapy$499,103
R01 · FY2015 · AR · contact PI
Enhancing bone strength using combination drug therapy$450,706
R01 · FY2014 · AR · contact PI
Enhancing bone strength using combination drug therapy$38,958
R01 · FY2014 · AR · contact PI
Enhancing bone strength using combination drug therapy$441,711
R01 · FY2013 · AR · contact PI
Enhancing bone strength using combination drug therapy$154,928
R01 · FY2013 · AR · contact PI
Enhancing bone strength using combination drug therapy$458,285
R01 · FY2012 · AR · contact PI
Bisphosphonate-related osteonecrosis of the jaw: Bridging the clinical-preclinica$114,345
R21 · FY2010 · DE · contact PI
Bisphosphonate-related osteonecrosis of the jaw: Bridging the clinical-preclinica$308,000
R21 · FY2009 · DE · contact PI